Hyqvia (Human Normal Immunoglobulin, Hyaluronidase (Human Recombinant))

Hyqvia is used in the management of primary immunodeficiency disorders, providing essential IgG antibodies to reduce infection risk.

• Primary Immunodeficiency Diseases: restores IgG levels and decreases frequency of infections.
• Common Variable Immunodeficiency (CVID): supplies missing antibodies to prevent recurrent infections.
• X‑linked Agammaglobulinemia (XLA): provides IgG replacement to reduce bacterial and viral infections.
• Severe Combined Immunodeficiency (SCID) post‑transplant: supports immune reconstitution after hematopoietic stem cell transplantation.

• Hyqvia delivers human normal immunoglobulin (IgG) subcutaneously, supplying passive immunity by replacing deficient antibodies. The recombinant hyaluronidase temporarily depolymerizes hyaluronic acid in the extracellular matrix, increasing tissue permeability and allowing a larger volume of immunoglobulin to be dispersed and absorbed efficiently from the injection site.

Hyqvia may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Injection site reactions: redness, swelling, or pain at the administration site.
• Headache: mild to moderate intensity.
• Fatigue: transient tiredness following infusion.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: blood clots that may lead to serious complications.
• Renal dysfunction: impaired kidney function, especially in patients with pre‑existing renal disease.
• Aseptic meningitis: inflammation of the meninges without infection.

Before initiating Hyqvia therapy, several safety considerations should be observed.

• Baseline IgG assessment: determine immunoglobulin levels to guide dosing.
• Renal function monitoring: check creatinine and eGFR regularly.
• Hypersensitivity screening: evaluate for prior allergic reactions to immunoglobulins or hyaluronidase.
• Thrombotic risk evaluation: avoid in patients with active clotting disorders.
• Caution with anticoagulants: monitor for bleeding tendencies.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hyqvia can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Live vaccines: may cause uncontrolled infection due to immunosuppression.
• Immunosuppressants (e.g., rituximab): can diminish the efficacy of immunoglobulin replacement.
• Anticoagulants: increased risk of bleeding at injection sites due to hyaluronidase activity.
• ACE inhibitors: potential for enhanced angioedema.

Moderate Interactions (Monitor Closely)

• Antibiotics: overlapping toxicity, especially nephrotoxic agents.
• Diuretics: may affect renal clearance of immunoglobulin.
• Non‑live vaccines: efficacy may be reduced, monitor antibody response.
• NSAIDs: may increase incidence of injection site reactions.